Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
11.94
+0.08 (0.67%)
At close: Jun 12, 2026, 4:00 PM EDT
11.88
-0.06 (-0.50%)
After-hours: Jun 12, 2026, 4:10 PM EDT
Contineum Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
51
Market Cap
446.39M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 50.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sutro Biopharma | 99.61M |
| Autolus Therapeutics | 92.62M |
| Arvinas | 89.40M |
| 4D Molecular Therapeutics | 88.24M |
| Assembly Biosciences | 71.10M |
| Prothena Corporation | 57.94M |
| C4 Therapeutics | 34.86M |
| Neurogene | 925.00K |
CTNM News
- 3 days ago - Contineum Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 11 days ago - Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference - Business Wire
- 24 days ago - Contineum Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Contineum price target raised to $16 from $14 at Morgan Stanley - TheFly
- 4 weeks ago - Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference - Business Wire
- 4 weeks ago - Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference - Business Wire
- 5 weeks ago - Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones - Business Wire